“…The NIAS has been widely used in a number of settings with diverse clinical and non-clinical populations (Zickgraf et al, 2023) and norms for the general population have been established (Zickgraf & Ellis, 2018). A large number of translations and adaptations of the NIAS have been made (e.g., Billman Miller et al, 2024; Fekih-Romdhane et al, 2023; He et al, 2021; Medina-Tepal et al, 2023; Van Ouytsel et al, 2024; Ziolkowska et al, 2022), including development of a parent-report version (Ziolkowska et al, 2022). The NIAS has also been used to examine the potential comorbidity of ARFID in individuals with gastrointestinal disorders, including gastroparesis, functional dyspepsia, achalasia, celiac disease, eosinophilic esophagitis, and inflammatory bowel disease (Burton Murray et al, 2020; Fink et al, 2022; Kaul et al, 2024; Robelin et al, 2021; Yelencich et al, 2022).…”